Cost effectiveness of high-dose chemotherapy with autologous stem cell support as initial treatment of aggressive non-Hodgkin's lymphoma

PharmacoEconomics

Volumn 27, Issue 1, 2009, Pages 55-68

  Fagnoni, Philippe ^a,b   Milpied, Noel ^c   Limat, Samuel ^a,b   Deconinck, Eric ^a,d   Nerich, Virginie ^a,d   Foussard, Charles ^e   Colombat, Philippe ^f   Harousseau, Jean Luc ^g   Woronoff Lemsi, Marie Christine ^a,d  

^a UNIVERSITY HOSPITAL OF BESANÇON   (France)

^b UNIVERSITÉ DE BOURGOGNE   (France)

^c BORDEAUX UNIVERSITY HOSPITAL   (France)

^d UNIVERSITÉ DE FRANCHE COMTÉ   (France)

^e ANGERS UNIVERSITY HOSPITAL   (France)

^f UNIVERSITY HOSPITAL OF TOURS   (France)

^g NANTES UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MELPHALAN; METHOTREXATE; PREDNISONE; VINCRISTINE; VINDESINE;

ADOLESCENT; ADULT; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BOOTSTRAPPING; CANCER CHEMOTHERAPY; CLINICAL TRIAL; COHORT ANALYSIS; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG MEGADOSE; FEMALE; FOLLOW UP; HOSPITAL COST; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NONHODGKIN LYMPHOMA; OPEN STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; PUBLIC HEALTH INSURANCE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; COST-BENEFIT ANALYSIS; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PREDNISOLONE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TIME FACTORS; TRANSPLANTATION, AUTOLOGOUS; VINCRISTINE;

EID: 59049101448     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200927010-00006     Document Type: Article

References (35)

1. Beard SM, Wall L, Gaffney L, et al. Aggressive non-Hodgkin's lymphoma: economics of high-dose therapy. Pharmacoeconomics 2004; 22: 207-24
2. Copelan EA. Hematopoietic stem-cell transplantation. N Engl J Med 2006; 354: 1813-26
3. Coiffier B. State-of-the-art therapeutics: diffuse large B-cell lymphoma. J Clin Oncol 2005; 23: 6387-93
4. Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333: 1540-5
5. Haioun C, Lepage E, Gisselbrecht C, et al. Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol. A groupe d'Etude des Lymphomes de l'Adulte study. J Clin Oncol 2000; 18: 3025-30
6. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235-42
7. Milpied N, Deconinck E, Gaillard F, et al. Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. N Engl J Med 2004; 350: 1287-95
8. Marie JP, Bisserbe S, Bouaziz C, et al. A program for medical use of information systems: validity of calculation of direct costs for the initial treatment of acute myeloblastic leukaemia [in French]. Presse Med 1992; 21: 1364-8
9. Borella L, Peuverel P, Sauvage M, et al. A study based on national DRG data to evaluate work load and practice relating to cancer patients in not-for-profit hospitals [in French]. Rev Epidémiol Santé Publique 2000; 48: 53-70
10. Messori A, Bonistalli L, Costantini M, et al. Cost-effectiveness of autologous bone marrow transplantation in patients with relapsed non-Hodgkin's lymphoma. Bone Marrow Transplant 1997; 19: 275-81
11. Beard SM, Lorigan PC, Sampson FC. The cost-effectiveness of high dose chemotherapy in the treatment of relapsed Hodgkin's disease and non-Hodgkin's lymphoma. Br J Cancer 2000; 82: 81-4
12. Hartmann O, Le Corroller AG, Blaise D, et al. Peripheral blood stem cell and bone marrow transplantation for solid tumors and lymphomas: hematologic recovery and costs. A randomized, controlled trial. Ann Intern Med 1997; 126: 600-7
13. Smith TJ, Hillner BE, Schmitz N, et al. Economic analysis of a randomized clinical trial to compare filgrastim-mobilized peripheral-blood progenitor-cell transplantation and autologous bone marrow transplantation in patients with Hodgkin's and non-Hodgkin's lymphoma. J Clin Oncol 1997; 15: 5-10
14. van Agthoven M, Vellenga E, Fibbe WE, et al. Cost analysis and quality of life assessment comparing patients undergoing autologous peripheral blood stem cell transplantation or autologous bone marrow transplantation for refractory or relapsed non-Hodgkin's lymphoma or Hodgkin's disease: a prospective randomised trial. Eur J Cancer 2001; 37: 1781-9
15. Uyl-de Groot CA, Ossenkoppele GJ, Buijt I, et al. Costs of peripheral blood progenitor cell transplantation using whole blood mobilised by filgrastim as compared with autologous bone marrow transplantation in non-Hodgkin's lymphoma. Pharmacoeconomics 1999; 15: 305-11
16. Woronoff-Lemsi MC, Arveux P, Limat S, et al. Cost comparative study of autologous peripheral blood progenitor cells (PBPC) and bone marrow (ABM) transplantations for non-Hodgkin's lymphoma patients. Bone Marrow Transplant 1997; 20: 975-82
17. Hornberger JC, Best JH. Cost utility in the United States of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for the treatment of elderly patients with diffuse large B-cell lymphoma. Cancer 2005; 103: 1644-51
18. Organisation for Economic Co-operation and Development (OECD). Consumer price indices [online]. Available from URL: http://www.oecd.org [Accessed 2008 Aug 29]
19. Briggs AH, Wonderling DE, Mooney CZ. Pulling cost-effectiveness analysis up by its bootstraps: a nonparametric approach to confidence interval estimation. Health Econ 1997; 6: 327-40
20. van Agthoven M, Sonneveld P, Verdonck LF, et al. Cost determinants in aggressive non-Hoddgkin's lymphoma. Haematologica 2005; 90: 661-71
21. Gelber RD, Gelman RS, Goldhirsch A. Quality of life oriented endpoint for comparing therapies. Biometrics 1989; 45: 781-95
22. Pickard AS, Wilke CT, Lin HW, et al. Health utilities using the EQ-5D in studies of cancer. Pharmacoeconomics 2007; 25: 365-84
23. Doorduijn J, Buijt I, van der Holt B, et al. Self-reported quality of life in elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP therapy. Eur J Haematol 2005; 75: 116-23
24. Doorduijn J, Buijt I, Uyl-de Groot C, et al. Quality of life in elderly patients with aggressive non-Hodgkin's lymphoma (NHL) treated with CHOP. Blood 2001; 98: 430a
25. The EuroQol group. EuroQol: a new facility for the measurement of health-related quality of life. Health Policy 1990; 16: 199-208
26. Jönsson B. Economics of drug treatment: for which patients is it cost-effective to lower cholesterol? Lancet 2001; 358: 1251-6
27. Earle CC, Chapman RH, Baker CS, et al. Systematic overview of cost-utility assessments in oncology. J Clin Oncol 2000; 18: 3302-17
28. O'Brien BJ, Heyland D, Richardson WS, et al. User's guides to the medical literature: how to use an article on economic analysis of clinical practice. What are results and will they help me in caring for my patients? JAMA 1997; 277: 1802-8
29. Best JH, Hornberger J, Proctor SJ, et al. Cost-effectiveness analysis of rituximab combined with chop for treatment of diffuse large B-cell lymphoma. Value Health 2005; 8: 462-70
30. Mishra V, Andresen S, Brinch L, et al. Cost of autologous peripheral blood stem cell transplantation: the Norwegian experience from a multicenter cost study. Bone Marrow Transplant 2005; 35: 1149-53
31. Limat S, Woronoff-Lemsi MC, Milpied N, et al. Effect of cell determinant (CD)34+ cell dose on the cost and consequences of peripheral blood stem cell transplantation for non-Hodgkin's lymphoma patients in front-line therapy. Eur J Cancer 2000; 36: 2360-7
32. Limat S, Woronoff-Lemsi MC, Deconinck E, et al. Cost-effectiveness of CD34+ dose in peripheral blood progenitor cell transplantation for non-Hodgkin's lymphoma patients: a single centre study. Bone Marrow Transplant 2000; 25: 997-1002
33. Bennett CL, Armitage JL, Armitage GO, et al. Costs of care and outcomes for high-dose therapy and autologous transplantation for lymphoid malignancies: results from the University of Nebraska 1987 through 1991. J Clin Oncol 1995; 13: 969-73
34. Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2005; 23: 4117-26
35. Gisselbrecht C ,Mounier N. Managing large cell lymphoma. Ann Oncol 2006; 17: iv8-11